دورية أكاديمية
أعرض في EDS

Silymarin Supplementation in Active Rheumatoid Arthritis: Outcomes of a Pilot Randomized Controlled Clinical Study.

التفاصيل البيبلوغرافية
العنوان: Silymarin Supplementation in Active Rheumatoid Arthritis: Outcomes of a Pilot Randomized Controlled Clinical Study.
المؤلفون: Zugravu GS; Faculty of Pharmacy, Grigore T. Popa University of Medicine and Pharmacy, 16, Universitatii Street, 700115 Iasi, Romania.; Clinical Rehabilitation Hospital, 14, Pantelimon Halipa Street, 700661 Iasi, Romania., Pintilescu C; Faculty of Economics and Business Administration, Alexandru Ioan Cuza University of Iasi, 22, Carol I Boulevard, 700505 Iasi, Romania., Cumpat CM; Clinical Rehabilitation Hospital, 14, Pantelimon Halipa Street, 700661 Iasi, Romania.; Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, 16, Universitatii Street, 700115 Iasi, Romania., Miron SD; Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, 16, Universitatii Street, 700115 Iasi, Romania., Miron A; Faculty of Pharmacy, Grigore T. Popa University of Medicine and Pharmacy, 16, Universitatii Street, 700115 Iasi, Romania.
المصدر: Medicina (Kaunas, Lithuania) [Medicina (Kaunas)] 2024 Jun 18; Vol. 60 (6). Date of Electronic Publication: 2024 Jun 18.
نوع المنشور: Journal Article; Randomized Controlled Trial
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 9425208 Publication Model: Electronic Cited Medium: Internet ISSN: 1648-9144 (Electronic) Linking ISSN: 1010660X NLM ISO Abbreviation: Medicina (Kaunas) Subsets: MEDLINE
أسماء مطبوعة: Publication: 2018- : Basel, Switzerland : MDPI
Original Publication: Kaunas : Lietuvos gydytojų sąjunga
مواضيع طبية MeSH: Silymarin*/therapeutic use , Silymarin*/administration & dosage , Arthritis, Rheumatoid*/drug therapy , Dietary Supplements*, Humans ; Female ; Pilot Projects ; Male ; Middle Aged ; Adult ; Treatment Outcome ; Antirheumatic Agents/therapeutic use ; Antirheumatic Agents/administration & dosage ; Aged
مستخلص: Background and Objectives : Coadministration of natural products to enhance the potency of conventional antirheumatic treatment is of high interest. This study aimed to assess the impact of administration of silymarin (a nutritional supplement) in patients with active rheumatoid arthritis under treatment with conventional disease-modifying antirheumatic drugs. Materials and Methods : One-hundred and twenty-two patients diagnosed with active rheumatoid arthritis and treated with conventional disease-modifying antirheumatic drugs were randomly assigned to either control or intervention groups; the latter was supplemented with silymarin (300 mg/day) for 8 weeks. Indicators of disease activity, inflammatory markers, disease activity and disability indices, European League Against Rheumatism responses, fatigue, depression, and anxiety scores were determined at baseline and week 8. Results : Silymarin supplementation significantly reduced the number of tender and swollen joints, duration of morning stiffness, severity of pain, disease activity and disability indices, European League Against Rheumatism responses, levels of fatigue, depression, and anxiety. According to our results, silymarin substantially improved patients' general condition. Conclusions : Our study provides evidence for the benefits of silymarin supplementation to disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis.
References: Pharmacol Res. 2021 Jul;169:105618. (PMID: 33878447)
Acta Reumatol Port. 2011 Oct-Dec;36(4):364-9. (PMID: 22472926)
Turk J Med Sci. 2021 Nov 13;51(6):3008-3016. (PMID: 34773692)
Phytomedicine. 2012 Oct 15;19(13):1200-5. (PMID: 22925727)
Rheumatology (Oxford). 2006 Jul;45(7):885-9. (PMID: 16449363)
Nutr Neurosci. 2024 Feb 14;:1-11. (PMID: 38353101)
Antioxidants (Basel). 2023 Dec 06;12(12):. (PMID: 38136202)
Lancet. 2016 Oct 22;388(10055):2023-2038. (PMID: 27156434)
Clin Exp Rheumatol. 2005 Sep-Oct;23(5 Suppl 39):S14-8. (PMID: 16273780)
J Ethnopharmacol. 2021 Oct 28;279:114368. (PMID: 34197960)
Semin Arthritis Rheum. 2023 Oct;62:152249. (PMID: 37573754)
Naunyn Schmiedebergs Arch Pharmacol. 2024 May 27;:. (PMID: 38801454)
Arch Intern Med. 2006 May 22;166(10):1092-7. (PMID: 16717171)
Curr Med Chem. 2023;30(33):3775-3797. (PMID: 36424777)
Rheumatol Int. 2021 May;41(5):863-877. (PMID: 33175207)
Pak J Med Sci. 2015 Mar-Apr;31(2):393-7. (PMID: 26101498)
J Orthop Surg Res. 2021 Feb 20;16(1):147. (PMID: 33610183)
Saudi Med J. 2009 Jan;30(1):98-103. (PMID: 19139781)
Arthritis Res Ther. 2020 Oct 15;22(1):243. (PMID: 33059710)
Front Pharmacol. 2018 Apr 27;9:422. (PMID: 29755356)
Ann Rheum Dis. 2009 Jun;68(6):954-60. (PMID: 18490431)
Ann Rheum Dis. 2010 Jan;69(1):97-101. (PMID: 19346220)
Support Care Cancer. 2012 Feb;20(2):319-24. (PMID: 21243377)
BMC Musculoskelet Disord. 2016 Apr 11;17:155. (PMID: 27068100)
Antioxidants (Basel). 2024 Mar 24;13(4):. (PMID: 38671838)
J Intercult Ethnopharmacol. 2015 Apr-Jun;4(2):147-79. (PMID: 26401403)
J Am Acad Orthop Surg Glob Res Rev. 2018 Mar 23;2(3):e088. (PMID: 30211382)
Cells. 2021 Oct 23;10(11):. (PMID: 34831081)
Rheumatology (Oxford). 2024 May 3;63(6):1574-1581. (PMID: 37632771)
Arthritis Rheum. 1992 May;35(5):498-502. (PMID: 1575785)
Molecules. 2017 Nov 10;22(11):. (PMID: 29125572)
Iran J Allergy Asthma Immunol. 2017 Apr;16(2):99-106. (PMID: 28601049)
J Am Med Assoc. 1949 Jun 25;140(8):659-62. (PMID: 18150288)
Iran J Immunol. 2022 Dec;19(4):427-435. (PMID: 36585884)
Phytomedicine. 2000 Mar;7(1):21-4. (PMID: 10782486)
Front Neurosci. 2023 May 18;17:1159806. (PMID: 37274201)
Rheumatol Int. 2018 Nov;38(11):2147-2155. (PMID: 30159774)
Arthritis Rheum. 2010 Sep;62(9):2569-81. (PMID: 20872595)
Rheumatology (Oxford). 2011 Feb;50(2):401-9. (PMID: 21059675)
J Drugs Dermatol. 2022 Dec 1;21(12):1304-1310. (PMID: 36468967)
فهرسة مساهمة: Keywords: depression; fatigue; functional status; pain; rheumatoid arthritis; silymarin
المشرفين على المادة: 0 (Silymarin)
0 (Antirheumatic Agents)
تواريخ الأحداث: Date Created: 20240627 Date Completed: 20240627 Latest Revision: 20240629
رمز التحديث: 20240629
مُعرف محوري في PubMed: PMC11205411
DOI: 10.3390/medicina60060999
PMID: 38929616
قاعدة البيانات: MEDLINE
الوصف
تدمد:1648-9144
DOI:10.3390/medicina60060999